Abstract: In recent years, immune checkpoint inhibitors (ICI) have been a significant breakthrough in the treatment of lung cancer, leading to improved survival rates for patients with advanced disease. However, an increase in the number of treatment/drug options has made the choice of an appropriate treatment challenging. This article utilizes the Chinese Thoracic Oncology Group (CTONG) scoring system to assess the clinical value of ICI drugs in the initial treatment of advanced non-small cell lung cancer (NSCLC) in terms of efficacy, safety, quality of life, and compensation, providing reasonable guidance and optimize treatment strategies for improved patient outcomes. Moreover, the proposed score can indicate the demand for new drugs and indications. This can determine the direction of research focusing on the development of novel therapeutics and corresponding strategies for industry.